Read More Pharma Industry News MacroGenics exits GMP manufacturing operations as Bora expands U.S. biologics footprint MacroGenics’ $122.5 million Bora sale boosts MGNX cash flexibility while shifting GMP manufacturing to a CDMO model. bySoujanya RaviJuly 2, 2026